Discovery of a dual CCR2/CCR5 antagonist with a superior cardiovascular profile for the treatment of autoimmune diseases

被引：0
|
作者：
Hughes, Robert O. [1 ]
Rogier, D. Joseph [1 ]
Devraj, Rajesh [1 ]
Xue, Chu-Biao [2 ]
Cao, Ganfeng [2 ]
Turner, Steven R. [1 ]
Morton, Philip A. [1 ]
Keys, Kelly [1 ]
Covington, Maryanne [2 ]
Bond, Brian R. [1 ]
Yu, Ying [1 ]
Meade, Holly [1 ]
Hood, William F. [1 ]
Roeberds, Steve [1 ]
Newton, Robert [2 ]
Metcalf, Brian [2 ]
机构：
[1] Pfizer Res & Dev, Cambridge, MA 02451 USA
[2] Incyte Corp, Willmington, DE 19880 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 242卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
26-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Discovery of a Potent and Orally Bioavailable CCR2 and CCR5 Dual Antagonist
    Pasternak, Alexander
    Goble, Stephen D.
    Struthers, Mary
    Vicario, Pasquale P.
    Ayala, Julia M.
    Di Salvo, Jerry
    Kilburn, Ruth
    Wisniewski, Thomas
    DeMartino, Julie A.
    Mills, Sander G.
    Yang, Lihu
    ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (01): : 14 - 18
  • [2] Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases
    Zhao, Qihong
    JOURNAL OF LEUKOCYTE BIOLOGY, 2010, 88 (01) : 41 - 55
  • [3] A dual CCR2/CCR5 chemokine antagonist, BMS-813160?
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2011, 21 (12) : 1919 - 1924
  • [4] Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5
    Ogilvie, P
    Bardi, G
    Clark-Lewis, I
    Baggiolini, M
    Uguccioni, M
    BLOOD, 2001, 97 (07) : 1920 - 1924
  • [5] Eotaxin: A CCR2 antagonist and a CCR5 agonist on human monocytes
    Ogilvie, P
    Bardi, G
    Loetscher, P
    Baggiolini, M
    Uguccioni, M
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (03) : 532 - 532
  • [6] A New Application for Cenicriviroc, a Dual CCR2/CCR5 Antagonist, in the Treatment of Painful Diabetic Neuropathy in a Mouse Model
    Bober, Aleksandra
    Piotrowska, Anna
    Pawlik, Katarzyna
    Ciapala, Katarzyna
    Maciuszek, Magdalena
    Makuch, Wioletta
    Mika, Joanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
  • [7] Dual Targeting Of Ccr2 And Ccr5 For Treating Pulmonary Hypertension
    Parpaleix, A.
    Amsellem, V.
    Abid, S.
    Houssaini, A.
    Breau, M.
    Marcos, E.
    Sawaki, D.
    Bizard, E.
    Hubeau, C.
    Evans, S. E.
    Delcroix, M.
    Quarck, R.
    Adnot, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [8] BMS-813160: A Potent CCR2 and CCR5 Dual Antagonist Selected as a Clinical Candidate
    Cherney, Robert J.
    Anjanappa, Prakash
    Selvakumar, Kumaravel
    Batt, Douglas G.
    Brown, Gregory D.
    Rose, Anne, V
    Vuppugalla, Ragini
    Chen, Jing
    Pang, Jian
    Xu, Songmei
    Yarde, Melissa
    Tebben, Andrew J.
    Paidi, Venkatram Reddy
    Cvijic, Mary Ellen
    Mathur, Arvind
    Barrish, Joel C.
    Mandlekar, Sandhya
    Zhao, Qihong
    Carter, Percy H.
    ACS MEDICINAL CHEMISTRY LETTERS, 2021, 12 (11): : 1753 - 1758
  • [9] Dual CCR2/CCR5 antagonist treatment attenuates adipose inflammation, but not microvascular complications in ob/ob mice
    O'Brien, Phillipe D.
    Hinder, Lucy M.
    Parlee, Sebastian D.
    Hayes, John M.
    Backus, Carey
    Zhang, Hongyu
    Ma, Lijun
    Sakowski, Stacey A.
    Brosius, Frank C., III
    Feldman, Eva L.
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1468 - 1472
  • [10] Molecular determinants of antagonist interactions with chemokine receptors CCR2 and CCR5
    Dawson, John R. D.
    Kufareva, Irina
    BIOPHYSICAL JOURNAL, 2023, 122 (03) : 185A - 185A
12345